Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,293.10
(
-0.04%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 179808

Monday, 03/02/2015 2:42:00 PM

Monday, March 02, 2015 2:42:00 PM

Post# of 257302
B-I submits BLA for Pradaxa antidote, Idarucizumab:

http://finance.yahoo.com/news/boehringer-ingelheim-submits-biologics-license-130000907.html

Idarucizumab has BTD from the FDA.

Note: Factor Xa antidotes such as PTLA’s Andexanet alfa don’t work on Pradaxa, which is a direct thrombin inhibitor, not an FXa inhibitor.

See #msg-102641221 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now